A user shared their positive 3-month experience using finasteride, minoxidil, and vitamin D to treat hair loss, noting significant regrowth and minimal shedding. They also discussed potential side effects and the low likelihood of experiencing them, while being open to answering further questions.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.
The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user with long-term hair loss has been using topical minoxidil, finasteride, RU58841, ketoconazole, and dermastamping for 8 months. They are unsure if the new hairs are miniaturized or vellus.
A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.
Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).
FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
Excess Vitamin A and topical retinoids can cause diffuse hair shedding. The user suspects their chronic telogen effluvium may be linked to using adapalene, a topical retinoid.
User experienced hair loss after weight loss and started using finasteride 1mg and a multivitamin called HAIRGRO. They noticed increased oily skin and sebum production and are unsure if they should continue the multivitamin.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The conversation is about disappointment with hair loss progress despite using treatments like finasteride, minoxidil, nizoral, tretinoin, and a dermaroller. Direct sunlight revealed more hair loss than expected, prompting continued treatment and hope for improvement.
The user shared progress pictures showing significant hair regrowth from April 29 to May 16, 2024. They attribute their success to using spironolactone, vitamin D, viviscal, and minoxidil, and quitting vaping THC.
The user reports visible improvement in hair thickness after using 0.5mg Dutasteride, 2.5mg Minoxidil, and 2% Ketoconazole shampoo, along with supplements, over 3.5 months. Other users note slight improvement and suggest giving it more time.
Hair loss due to low Vitamin D levels improved significantly after taking 4000UI Vitamin D capsules and vitamin B supplements. The user noticed a reduction in hair shedding within a week.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The user has been using topical finasteride and minoxidil for a month to address hair thinning. They are experiencing shedding but have noticed small hairs on their temples.
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
A user is experiencing mild hair loss and is hesitant to try finasteride due to potential side effects. They are considering using Research Verified Hair Growth, which contains various vitamins and minerals, and are seeking opinions and experiences from others.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.